Akebia Therapeutics Inc’s filing revealed that its SVP, Chief Accounting Officer Malabre Richard C unloaded Company’s shares for reported $60150.0 on Jun 09 ’25. In the deal valued at $4.01 per share,15,000 shares were sold. As a result of this transaction, Malabre Richard C now holds 266,914 shares worth roughly $0.96 million.
Then, Malabre Richard C sold 13,334 shares, generating $47,069 in total proceeds. Upon selling the shares at $3.53, the SVP, Chief Accounting Officer now owns 266,914 shares.
Before that, Butler John P. sold 46,409 shares. Akebia Therapeutics Inc shares valued at $84,928 were divested by the CEO and President at a price of $1.83 per share. As a result of the transaction, Butler John P. now holds 2,557,921 shares, worth roughly $9.16 million.
A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Jefferies began covering AKBA with “Buy” recommendation on April 01, 2025.
Price Performance Review of AKBA
On Monday, Akebia Therapeutics Inc [NASDAQ:AKBA] saw its stock jump 0.56% to $3.58. Over the last five days, the stock has lost -6.53%. Akebia Therapeutics Inc shares have risen nearly 88.42% since the year began. Nevertheless, the stocks have risen 208.62% over the past one year. While a 52-week high of $4.08 was reached on 06/09/25, a 52-week low of $0.80 was recorded on 04/10/25.
Levels Of Support And Resistance For AKBA Stock
The 24-hour chart illustrates a support level at 3.52, which if violated will result in even more drops to 3.46. On the upside, there is a resistance level at 3.66. A further resistance level may holdings at 3.74.
